Regeneron Pharmaceuticals (REGN) Other Accumulated Expenses (2010 - 2020)

Regeneron Pharmaceuticals' Other Accumulated Expenses history runs 10 years deep, the most recent figure standing at $122.4 million for Q4 2020.

• In Q4 2020, Other Accumulated Expenses rose 44.0% year-over-year to $122.4 million; the TTM figure through Dec 2020 stood at $122.4 million (up 44.0% YoY), while the FY2020 annual figure was $122.4 million, up 44.0% from the prior year.
• Other Accumulated Expenses for Q4 2020 stood at $122.4 million, up from $96.9 million in the prior quarter.
• The five-year high for Other Accumulated Expenses was $122.4 million in Q4 2020, with the low at $267000.0 in Q4 2017.
• The 4-year median for Other Accumulated Expenses is $3.7 million (2016), against an average of $39.8 million.
• The sharpest annual moves came in 2016 and 2017: Other Accumulated Expenses jumped 518.22% in 2016, then plunged 93.51% in 2017.
• Regeneron Pharmaceuticals' Other Accumulated Expenses stood at $1.2 million in 2016, then slumped by 77.33% to $267000.0 in 2017, then jumped by 31735.21% to $85.0 million in 2019, then jumped by 44.0% to $122.4 million in 2020.
• Business Quant data shows REGN's Other Accumulated Expenses at $122.4 million in Q4 2020, $96.9 million in Q3 2020, and $103.8 million in Q2 2020.